N-(Phosphonacetyl)-l-aspartate (PALA) in advanced breast cancer: a phase II trial of the EORTC breast cancer cooperative group

R. Paridaens, H. T. Mouridsen, T. Palshof, G. Cocconi, A. van Oosterom, N. Rotmensz, R. Sylvester, J. C. Heuson, M. Rozencweig

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Twenty-nine evaluable patients with extensively pretreated breast cancer received PALA, a new pyrimidine antimetabolite. The drug was given by intravenous infusion over 60 min, at a daily dose of 2.5 g/m2 for 2 consecutive days. Courses were repeated at 2-week intervals and doses were escalated to toxicity. Two objective partial remissions were observed, lasting for 3 and 4.5 months respectively. Toxic effects were dose-related and consisted mainly of mucocutaneous manifestations, i.e., skin rashes, stomatitis, diarrhea, conjunctivitis and corneal ulcerations. Evidence of antitumor potential in far-advanced disease and lack of myelosuppression point to the need for additional trials of PALA in a more favorable selection of patients with breast cancer.

Original languageEnglish
Pages (from-to)67-70
Number of pages4
JournalEuropean Journal of Cancer and Clinical Oncology
Volume18
Issue number1
DOIs
Publication statusPublished - 1982

Fingerprint

Aspartic Acid
Breast Neoplasms
Antimetabolites
Stomatitis
Conjunctivitis
Poisons
Exanthema
Intravenous Infusions
Patient Selection
Diarrhea
Pharmaceutical Preparations
pyrimidine

ASJC Scopus subject areas

  • Oncology

Cite this

N-(Phosphonacetyl)-l-aspartate (PALA) in advanced breast cancer : a phase II trial of the EORTC breast cancer cooperative group. / Paridaens, R.; Mouridsen, H. T.; Palshof, T.; Cocconi, G.; van Oosterom, A.; Rotmensz, N.; Sylvester, R.; Heuson, J. C.; Rozencweig, M.

In: European Journal of Cancer and Clinical Oncology, Vol. 18, No. 1, 1982, p. 67-70.

Research output: Contribution to journalArticle

Paridaens, R. ; Mouridsen, H. T. ; Palshof, T. ; Cocconi, G. ; van Oosterom, A. ; Rotmensz, N. ; Sylvester, R. ; Heuson, J. C. ; Rozencweig, M. / N-(Phosphonacetyl)-l-aspartate (PALA) in advanced breast cancer : a phase II trial of the EORTC breast cancer cooperative group. In: European Journal of Cancer and Clinical Oncology. 1982 ; Vol. 18, No. 1. pp. 67-70.
@article{e57c8e5f20b9485cae5d0353939d7747,
title = "N-(Phosphonacetyl)-l-aspartate (PALA) in advanced breast cancer: a phase II trial of the EORTC breast cancer cooperative group",
abstract = "Twenty-nine evaluable patients with extensively pretreated breast cancer received PALA, a new pyrimidine antimetabolite. The drug was given by intravenous infusion over 60 min, at a daily dose of 2.5 g/m2 for 2 consecutive days. Courses were repeated at 2-week intervals and doses were escalated to toxicity. Two objective partial remissions were observed, lasting for 3 and 4.5 months respectively. Toxic effects were dose-related and consisted mainly of mucocutaneous manifestations, i.e., skin rashes, stomatitis, diarrhea, conjunctivitis and corneal ulcerations. Evidence of antitumor potential in far-advanced disease and lack of myelosuppression point to the need for additional trials of PALA in a more favorable selection of patients with breast cancer.",
author = "R. Paridaens and Mouridsen, {H. T.} and T. Palshof and G. Cocconi and {van Oosterom}, A. and N. Rotmensz and R. Sylvester and Heuson, {J. C.} and M. Rozencweig",
year = "1982",
doi = "10.1016/0277-5379(82)90026-8",
language = "English",
volume = "18",
pages = "67--70",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "1",

}

TY - JOUR

T1 - N-(Phosphonacetyl)-l-aspartate (PALA) in advanced breast cancer

T2 - a phase II trial of the EORTC breast cancer cooperative group

AU - Paridaens, R.

AU - Mouridsen, H. T.

AU - Palshof, T.

AU - Cocconi, G.

AU - van Oosterom, A.

AU - Rotmensz, N.

AU - Sylvester, R.

AU - Heuson, J. C.

AU - Rozencweig, M.

PY - 1982

Y1 - 1982

N2 - Twenty-nine evaluable patients with extensively pretreated breast cancer received PALA, a new pyrimidine antimetabolite. The drug was given by intravenous infusion over 60 min, at a daily dose of 2.5 g/m2 for 2 consecutive days. Courses were repeated at 2-week intervals and doses were escalated to toxicity. Two objective partial remissions were observed, lasting for 3 and 4.5 months respectively. Toxic effects were dose-related and consisted mainly of mucocutaneous manifestations, i.e., skin rashes, stomatitis, diarrhea, conjunctivitis and corneal ulcerations. Evidence of antitumor potential in far-advanced disease and lack of myelosuppression point to the need for additional trials of PALA in a more favorable selection of patients with breast cancer.

AB - Twenty-nine evaluable patients with extensively pretreated breast cancer received PALA, a new pyrimidine antimetabolite. The drug was given by intravenous infusion over 60 min, at a daily dose of 2.5 g/m2 for 2 consecutive days. Courses were repeated at 2-week intervals and doses were escalated to toxicity. Two objective partial remissions were observed, lasting for 3 and 4.5 months respectively. Toxic effects were dose-related and consisted mainly of mucocutaneous manifestations, i.e., skin rashes, stomatitis, diarrhea, conjunctivitis and corneal ulcerations. Evidence of antitumor potential in far-advanced disease and lack of myelosuppression point to the need for additional trials of PALA in a more favorable selection of patients with breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=0020035037&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020035037&partnerID=8YFLogxK

U2 - 10.1016/0277-5379(82)90026-8

DO - 10.1016/0277-5379(82)90026-8

M3 - Article

C2 - 6211361

AN - SCOPUS:0020035037

VL - 18

SP - 67

EP - 70

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 1

ER -